CJC-1295 (without DAC) and Pitavastatin Interaction
CJC-1295 (without DAC) and Pitavastatin have a synergistic interaction with 60% confidence. Pitavastatin helps manage estrogen conversion from CJC-1295 (without DAC). This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen. These compounds primarily affect different organ systems.
Compound Profiles
CJC-1295 (without DAC)
Short-Acting Growth Hormone Releasing Hormone Analog
Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.
View full profilePitavastatin
HMG-CoA Reductase Inhibitor | Low-Interaction Statin
Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take CJC-1295 (without DAC) with Pitavastatin?
Yes, CJC-1295 (without DAC) and Pitavastatin can generally be taken together. Pitavastatin helps manage estrogen conversion from CJC-1295 (without DAC). This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Is CJC-1295 (without DAC) and Pitavastatin safe together?
Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: teratogenic. Monitor accordingly.
What are the interactions between CJC-1295 (without DAC) and Pitavastatin?
Pitavastatin helps manage estrogen conversion from CJC-1295 (without DAC). This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen. This assessment has 60% confidence and is inferred from pharmacological mechanism analysis.
How should I time CJC-1295 (without DAC) and Pitavastatin?
CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Pitavastatin has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.